Lymphoma  >>  Gazyva (obinutuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

93 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT00576758 / 2008-003460-19: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Checkmark BSH 2015
Apr 2015 - Apr 2015: BSH 2015
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data
More
Completed
2
175
US, Canada, Europe, RoW
obinutuzumab (RO5072759), RO5072759, GA101, GAZYVA®, rituximab
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
09/11
03/13
NCT01414205: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark For CLL
Jun 2013 - Jun 2013: For CLL
Completed
2
80
US
Obinutuzumab, RO5072759; GA101, Corticosteroids
Genentech, Inc.
Lymphocytic Leukemia, Chronic
03/13
03/16
NCT00517530 / 2007-001103-37: A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

Checkmark B-cell non-Hodgkin lymphoma
Dec 2015 - Dec 2015: B-cell non-Hodgkin lymphoma
Checkmark Indolent non-Hodgkin lymphoma
Jul 2013 - Jul 2013: Indolent non-Hodgkin lymphoma
Checkmark relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma
More
Completed
2
134
Europe
Obinutuzumab, RO5072759, GA101
Hoffmann-La Roche
Lymphoma
11/13
11/13
GATHER, NCT01414855: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
100
US
obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Genentech, Inc.
Lymphoma, B-Cell
12/13
12/16
NCT01868893: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Checkmark Presentation of data for stage II CLL11 trial at ASH 2013
Dec 2013 - Dec 2013: Presentation of data for stage II CLL11 trial at ASH 2013
Completed
2
20
US
Obinutuzumab, RO 5072759, GA101, Chlorambucil
Genentech, Inc.
Chronic Lymphocytic Leukemia
01/14
01/14
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B.

Not yet recruiting
2
90
Europe
Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag
Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01889797: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Terminated
2
32
US
Arm A: Rituximab, IDEC-C2B8, Chimeric anti-CD20 monoclonal antibody, Rituxan, NSC# 687451, Arm B: GA101, Obinutuzumab, RO5072759, huMAB
PrECOG, LLC., Genentech, Inc.
Indolent Non-Hodgkin's Lymphoma
04/16
08/16
2016-001033-27: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia (MW) REMODEL - WM3 Etude ouverte de phase II évaluant l’efficacité d’un traitement «sans chimiothérapie » par l’association de l’Idelalisib avec l’Obinutuzumab chez les patients atteints de la Maladie de Waldenström (MW)

Ongoing
2
50
Europe
Obinutuzumab, R05072759/F06-01, Concentrate for solution for infusion, Film-coated tablet, Gazyvaro, Zydelig
FILO, Roche, GILEAD
Waldenstrom’s Macroglobulinemia (MW) Macroglobulinémie de Waldenstrom (MW), Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia Patient en rechute ou réfractaire d'une macroglobulinémie de Waldenstrom, Diseases [C] - Cancer [C04]
 
 
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens

Ongoing
2
70
Europe
obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro
HOVON Foundation, Dutch Cancer Society, Roche
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
GIBB, NCT02320487: A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Completed
2
102
US
Bendamustine, Treanda, Levact, Obinutuzumab, GA101, Gazyva™, RO5072759
Genentech, Inc.
Chronic Lymphocytic Leukemia
11/16
02/19
ROMULUS, NCT01691898 / 2011-004377-84: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Checkmark ROMULUS trial of polatuzumab + Gazyva/Rituxan for r/r FL and DLBCL at ASH 2016
Dec 2016 - Dec 2016: ROMULUS trial of polatuzumab + Gazyva/Rituxan for r/r FL and DLBCL at ASH 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ROMULUS trial for NHL
More
Completed
2
231
Europe, Canada, US
Obinutuzumab, GA101, Gazyva, Gazyvaro, Pinatuzumab Vedotin, DCDT2980S, Polatuzumab Vedotin, DCDS4501A, Rituximab, MabThera/Rituxan
Genentech, Inc.
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
03/17
02/19
ICLL-07, NCT02666898: Phase II Trial GA101 Inbrutinib B CLL

Completed
2
135
Europe
GA101, Obinutuzumab, Ibrutinib, Imbruvica, Cyclophosphamide, Endoxan, Fludarabine, Fludara
French Innovative Leukemia Organisation, Roche Pharma AG, Janssen-Cilag Ltd.
Leukemia, Lymphocytic, Chronic, B-Cell
05/17
03/18
2016-003579-22: A Study Exploring the Safety and Efficacy of Atezolizumab Administered in Combination with Obinutuzumab or Rituximab Anti-CD20 Therapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma and Waldenström Macroglobulinemia Estudio fase II de seguridad y eficacia de Atezolizumab administrado en combinación con terapia anti-CD20 Obinutuzumab o Rituximab en pacientes con linfoma de células del manto o de la zona marginal y macroglobulinemia de Waldenström refractarios o en recaída.

Completed
2
120
Europe
Atezolizumab, MabThera 500 mg concentrate for solution for infusion, MabThera 1400 mg solution for subcutaneous injection, RO5541267, RO0452294, Solution for infusion, , Solution for injection, Gazyvaro 1,000 mg, MabThera 500 mg concentrate for solution for infusion, MabThera 1400 mg solution for subcutaneous injection
Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche, F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F.Hoffman-La Roche Ltd.
Relapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM) LINFOMA DE CÉLULAS DEL MANTO, LINFOMA DE LA ZONA MARGINAL, MACROGLOBULINEMIA DE WALDENSTRÖM, MCL is a B-cell non-Hodgkin lymphoma (lymph nodes, spleen, etc); MZL (B-cell lymphoma) arise from post-germinal center marginal zone B-cell; WM is a lymphoplasmacytic lymphoma in the bone marrow. LCM linfoma no Hodgkin de células B (ganglios linfáticos, bazo, etc); LZM (linfoma de células B) zona marginal del centro post-germinal de células B; MW linfoma linfoplasmocitario en la médula ósea., Diseases [C] - Cancer [C04]
 
 
NCT02071225 / 2013-003388-79: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Completed
2
72
Europe
bendamustine, obinutuzumab, RO5072759
Hoffmann-La Roche
Chronic Lymphocytic Leukemia
11/18
11/18
NCT02499003 / 2014-004780-21: GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Completed
2
70
Europe
Obinutuzumab and Pixantrone, GA101 /Gazyvaro, Pixuvri
Johannes Gutenberg University Mainz, Roche Pharma AG, Servier
Lymphoma, Non-Hodgkin
01/19
01/22
NCT02983617 / 2016-002768-15: Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Completed
2
36
Europe
Tirabrutinib, GS-4059, ONO-4059, Entospletinib, GS-9973, Obinutuzumab, Gazyvaro®, Gazyva®, GA101
Gilead Sciences, German CLL Study Group
Chronic Lymphocytic Leukemia
02/19
10/20
OBI-1, NCT03679455 / 2016-005053-20: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia,

Recruiting
2
30
Europe
Obinutuzumab 25 MG/ML, Gazyvaro
Polish Myeloma Consortium, Roche Pharma AG, Bioscience, S.A.
Waldenstrom Macroglobulinemia
04/19
12/22
CLLTX1, NCT03153514 / 2015-000568-32: Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

Terminated
2
3
Europe
Obinutuzumab, GA-101, Gazyva
German CLL Study Group, Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Richter's Transformation
05/19
06/19
2018-001229-18: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. Idelalisib (I) in combinazione con Obinutuzumab (G) per il trattamento di pazienti con linfoma follicolare ricaduto/refrattario: studio multicentrico di fase II a braccio singolo.

Not yet recruiting
2
43
Europe
Zydelig, GAZYVARO, [IMP1], [Obinutuzumab], Capsule, hard, Concentrate for solution for infusion, Zydelig, Gazyvaro
FONDAZIONE ITALIANA LINFOMI ONLUS, GILEAD, ROCHE
recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02968563 / 2015-003909-42: Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed
2
35
Europe
Tirabrutinib, GS-4059, Idelalisib, Zydelig®, GS-1101, CAL-101, Obinutuzumab, Gazyvaro®, Gazyva®, GA101
Gilead Sciences, German CLL Study Group
Chronic Lymphocytic Leukemia
06/19
01/21
NCT02371590: Lenalidomide and Obinutuzumab for Previously Untreated CLL

Withdrawn
2
0
US
Lenalidomide, Revlimid, Obinutuzumab, Gazyva
University of California, San Diego, Celgene Corporation, Genentech, Inc.
Chronic Lymphocytic Leukemia
12/19
12/22
OPERA PLRG-10, NCT03229382 / 2015-005439-41: Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Terminated
2
1
Europe
Obinutuzumab, Gazyvaro, GA101
Polish Lymphoma Research Group, Roche Pharma AG
Mantle Cell Lymphoma
01/20
01/20
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia

Not yet recruiting
2
40
Europe
Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax)
Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG
Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04]
 
 
2018-004038-13: Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor Burden

Not yet recruiting
2
102
Europe
Copanlisib, Obinutuzumab, BAY 80-6946, RO5072759/F06-01, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Gazyvaro
Klinikum der Universität München, Bayer HealthCare Pharmaceuticals Inc., Roche Pharma AG
Follicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated), Follicular Lymphoma with need of treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02750670: Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed
2
30
Canada
Obinutuzumab, GAZYVA, Gemcitabine, Dexamethasone, Decadron, Cisplatin
University Health Network, Toronto, Hoffmann-La Roche, Ozmosis Research Inc.
Lymphoma, Non-Hodgkin's
09/20
02/21
NCT02736617: Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Completed
2
10
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
06/21
06/21
2021-000311-23: Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Ibrutinib e Obinutuzumab come trattamento di prima linea per pazienti affetti dalla Leucemia Linfatica Cronica

Not yet recruiting
2
53
Europe
NA, Gazyvaro, [NA], [Gazyvaro], Capsule, hard, Concentrate for solution for injection, imbruvica, gazyvaro
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, Diseases [C] - Cancer [C04]
 
 
NCT02987400 / 2016-001760-10: Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Completed
2
22
Europe
Venetoclax, GA-101, Obinutuzumab, Gazyvaro
Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG
Lymphoma, Large B-Cell, Diffuse
10/21
10/21
GAZAI, NCT03341520 / 2016-002059-89: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Active, not recruiting
2
89
Europe
Obinutuzumab Injection [Gazyva], Gazyvaro, Low dose radiation Therapy (LDRT)
Heidelberg University, Roche Pharma AG
Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma, Stage I Follicular Lymphoma Grade 1, Stage II Follicular Lymphoma Grade 2
11/21
05/24
GABe2016, NCT03492775 / 2016-000755-27: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed
2
46
Europe
Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin
Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG
Indolent Non-hodgkin Lymphoma
11/21
12/22
CLL2-GiVe, NCT02758665 / 2015-004606-41: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Checkmark From CLL2GIVe trial in combination with venetoclax & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Jun 2020 - Jun 2020: From CLL2GIVe trial in combination with venetoclax & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Checkmark From CLL2GIVe trial in combination with Imbruvica & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Jun 2020 - Jun 2020: From CLL2GIVe trial in combination with Imbruvica & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Completed
2
41
Europe
ibrutinib, obinutuzumab, venetoclax
University of Ulm, German CLL Study Group, Roche Pharma AG, Janssen-Cilag Ltd., AbbVie
Leukemia, Lymphocytic, Chronic
01/22
03/22
NCT02689869 / 2014-005164-15: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Active, not recruiting
2
98
Europe
Ibrutinib, Imbruvica, GA 101, Obinutuzumab
Ludwig-Maximilians - University of Munich, Hoffmann-La Roche, Janssen-Cilag G.m.b.H
Indolent Non-Hodgkin Lymphoma
04/22
07/22
ROSEWOOD, NCT03332017 / 2017-001552-54: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Active, not recruiting
2
217
Europe, Canada, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Obinutuzumab, Gazyva
BeiGene
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
10/21
10/24
NCT04059081: A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Unknown status
2
31
RoW
Obinutuzumab
Deok-Hwan Yang, Roche Pharma AG
Chronic Lymphocytic Leukemia
07/22
07/22
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio.

Not yet recruiting
2
78
Europe
Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus
Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
23
US
Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382
Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
09/24
04/26
NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting
2
40
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc.
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
10/24
04/25
17P.176, NCT03198026: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Recruiting
2
30
US
Ibrutinib, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, 936563-96-1, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, Gazyva, R7159, RO 5072759, GA-101, GA101, huMAB(CD20), RO-5072759, RO5072759, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Genentech, Inc., Pharmacyclics LLC.
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
12/24
02/31
NCT02498951: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Terminated
2
32
US
Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment
OHSU Knight Cancer Institute, Genentech, Inc., National Cancer Institute (NCI), Oregon Health and Science University, Providence Health & Services
Central Nervous System B-Cell Non-Hodgkin Lymphoma
03/24
03/24
NCT04883437: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Recruiting
2
49
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, AstraZeneca, National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
01/24
01/24
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
NCT03580928: Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Venetoclax and Obinutuzumab for 1L CLL at ASH 2022
Active, not recruiting
2
72
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Dana-Farber Cancer Institute, AstraZeneca, Genentech, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL)
04/24
12/27
NCT06333262: Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab
Inhye Ahn, Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/27
02/29
NCI-2024-00209, NCT06213311: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Recruiting
2
40
US
Glofitamab, RO7082859, RG6026, Obinutuzumab, GA101, Gazyva, RO5072759, Axi-cel, Axicabtagene ciloleucel, KTE-C19, KTE-X19
M.D. Anderson Cancer Center, Genentech, Inc., Kite, A Gilead Company
B Cell Lymphoma
01/25
01/27
OLYMP-1, NCT03322865 / 2017-003149-56: Obinutuzumab in Marginal Zone Lymphoma

Active, not recruiting
2
56
Europe
Obinutuzumab, GA101
Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG
Marginal Zone Lymphoma
06/24
11/28
NCI-2024-00054, NCT06252675: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
50
US
Obinutuzumab, Anti-CD20 Monoclonal Antibody R715, huMAB(CD20), RO5072759, Glofitamab, Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO7082859, Pirtobrutinib, LOXO-305, Tumor Imaging, FDG-PET, Computed Tomography (CT), Biospecimen Collection, Biological Sample Collection, ClonoSeq Assay, ClonoSeq, Bone Marrow Biopsy, Biopsy of Bone Marrow
C. Babis Andreadis, Eli Lilly and Company, Genentech, Inc., Adaptive Biotechnologies
Mantle Cell Lymphoma
07/28
07/28
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
12/25
12/25
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
12/24
12/25
NCT03824483: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Recruiting
2
230
US
Zanubrutinib, Obinutuzumab, GA101, Venetoclax, ABT-199
Memorial Sloan Kettering Cancer Center, BeiGene USA, Inc., Roche-Genentech, Massachusetts General Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
02/25
02/25
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting
2
55
US
Acalabrutinib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/25
02/25
ReVenG, NCT04895436 / 2021-001037-39: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting
2
75
Europe, US, RoW
Venetoclax, Venclexta, ABT-199, GDC-0199, Obinutuzumab, GA101, Gazyva
AbbVie, F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia (CLL)
02/25
01/29
NCT04560322: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Recruiting
2
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Massachusetts General Hospital, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
NCI-2022-07625, NCT05536349: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab, GA101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, Valacyclovir, Allopurinol
M.D. Anderson Cancer Center, Loxo Oncology, Inc., The Leukemia and Lymphoma Society
Leukemia
04/25
04/25
NCT05105841: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
2
20
Japan
Venetoclax, Venclexta, ABT-199, GDC-0199, Ibrutinib, Imbruvica, Obinutuzumab, GA101, Gazyva, RO5072759
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/25
NCT06108232: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Recruiting
2
36
US
Obinutuzumab, GA101, Gazyva, RO5072759, CC-99282
M.D. Anderson Cancer Center, Bristol-Myers Squibb
Follicular Lymphoma, Tumor
12/25
12/27
NCT05783596: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Recruiting
2
50
US
Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Glofitamab, RO7082859
Reid Merryman, MD, Genentech, Inc.
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
01/26
01/29
NCT04447768: The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
2
100
US
Obinutuzumab, Venetoclax
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Chronic Lymphocytic Leukemia (CLL)
07/26
07/26
BruVenG, NCT05650723: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Recruiting
2
50
US
Zanubrutinib Pill, Brukinsa, Venetoclax Pill, Venclexta, Obinutuzumab Injection, Gazyva
Weill Medical College of Cornell University, BeiGene, Genentech, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
01/25
12/27
R-Pola-Glo, NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
80
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
09/27
09/28
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
PORTAL, NCT06071871: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Not yet recruiting
2
99
NA
Glofitamab, Columvi, Polatuzumab vedotin, Polivy, Obinutuzumab, Gazyvaro
University College, London, Hoffmann-La Roche
Large B-cell Lymphoma
01/27
07/28
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
CONTEMPO, NCT02391545 / 2014-005459-13: A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma

Checkmark Effect of duvelisib on components of the tumor microenvironment in previously untreated follicular lymphoma at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Effect of duvelisib on components of the tumor microenvironment in previously untreated follicular lymphoma at ASCO 2018 [screenshot]
Checkmark Data from CONTEMPO study in untreated follicular lymphoma
May 2018 - May 2018: Data from CONTEMPO study in untreated follicular lymphoma
Checkmark Duvelisib in combination with obinutuzumab or rituximab in front line FL (presented at ASH 2016)
More
Terminated
1b/2
55
Europe, US
Duvelisib, Copiktra, IPI-145, Rituximab, Rituxan/MabThera®, Obinutuzumab, GAZYVA/GAZYVARO™
SecuraBio
CD20+ Follicular Lymphoma
01/17
05/17
CAVALLI, NCT02055820 / 2013-003749-40: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Checkmark CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in front-line DLBCL at ASH 2016
Dec 2016 - Dec 2016: CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in front-line DLBCL at ASH 2016
Checkmark CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in first-line aggressive NHL at ASCO 2016
Jun 2016 - Jun 2016: CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in first-line aggressive NHL at ASCO 2016
Completed
1/2
267
Europe, Canada, US, RoW
Venetoclax, GDC-0199, ABT-199, Cyclophosphamide, Obinutuzumab, Rituximab, MabThera/Rituxan, Doxorubicin, Vincristine, Prednisone
Hoffmann-La Roche, AbbVie
Lymphoma, Non-Hodgkin
06/17
06/19
NCT02596971 / 2015-001364-19: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Nov 2022 - Nov 2022: Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Checkmark Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Nov 2015 - Nov 2015: Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Checkmark Initiation in atezolizumab in combination with Gazyva and CHOP for DLBCL
More
Completed
1/2
91
Europe, US, RoW
Atezolizumab, RO5541267; Tecentriq, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, RO5072759, Prednisone, Vincristine, Rituximab
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
04/18
05/20
NCT02729896 / 2015-004845-25: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Jun 2016 - Jun 2016: First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Completed
1/2
36
Europe, US
Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
Hoffmann-La Roche
Lymphoma
09/18
10/19
BO29562, NCT02631577 / 2015-002467-42: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Checkmark Initiation in atezolizumab in combination with Gazyva and lenalidomide for FL/DLBCL
Dec 2015 - Dec 2015: Initiation in atezolizumab in combination with Gazyva and lenalidomide for FL/DLBCL
Completed
1/2
38
Europe, US
Atezolizumab (MPDL3280A) [TECENTRIQ], Lenalidomide, Obinutuzumab
Hoffmann-La Roche
Lymphoma, Follicular
10/18
10/20
NCT01992653: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Checkmark In combination with immunochemotherapy in1L DLBCL
May 2019 - May 2019: In combination with immunochemotherapy in1L DLBCL
Checkmark Of polatuzumab + Gazyva/Rituxan + CHP in 1L DLBCL at ASH 2016
Dec 2016 - Dec 2016: Of polatuzumab + Gazyva/Rituxan + CHP in 1L DLBCL at ASH 2016
Completed
1/2
85
Europe, US
Cyclophosphamide, Doxorubicin, Obinutuzumab, Gazyva/Gazyvaro, Polatuzumab Vedotin, DCDS4501A, Prednisolone, Prednisone, Rituximab, MabThera/Rituxan
Genentech, Inc.
Lymphoma, Non Hodgkin
12/18
12/18
OAsIs, NCT02558816 / 2014-003740-13: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

Active, not recruiting
1/2
48
Europe
Ibrutinib + GA101 +GDC-0199, GA101 : Obinutuzumab, Ibrutinib, GDC-0199
Nantes University Hospital, Janssen, LP, Roche Pharma AG
Mantle Cell Lymphoma
04/19
10/25
NCT02624986 / 2015-002100-83: A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Terminated
1/2
25
Europe, US, RoW
Idasanutlin, RO5503781, Obinutuzumab, RO5072759, Rituximab, RO0452294
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
05/19
05/19
NCT03135262 / 2016-002480-34: A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
1/2
29
Europe, US, RoW
Idasanutlin, Obinutuzumab, Venetoclax, Rituximab
Hoffmann-La Roche
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
04/20
04/20
ENHANCE, NCT02406742 / 2014-003056-31: A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed
1/2
47
Europe, US
CC-122, Ibrutinib, Obinutuzumab
Celgene
Leukemia, Lymphocytic, Chronic, B-Cell
07/20
07/20
2020-000354-10: A study to evaluate how safe is CC-220, how is the body affected by CC-220, and a preliminary idea on how CC-220 works, when given alone or together with a medicine to treat cancer, in patients with lymphoma that is not responding to treatment or that has re-appeared.

Not yet recruiting
1/2
232
Europe
Iberdomide, CC-220, Concentrate for concentrate for solution for infusion, Solution for injection, Capsule, hard, Mabthera, Gazyvaro
Celgene Corporation, Celgene Corporation
Relapsed or refractory lymphoma including the following subtypes:Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and classical Hodgkin lymphoma., Different forms of type of blood cancer, called lymphoma, that is not responding to treatment or that has re-appeared., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03010358: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Completed
1/2
24
US
Entospletinib, ENTO, GS 9973, GS-9973, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pharmacological Study
Alexey Danilov, MD, Gilead Sciences, Oregon Health and Science University
Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
04/21
04/21
GO29365, NCT02257567 / 2014-001361-28: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Checkmark Regulatory approval in Japan in combination with bendamustine and rituximab for relapsed/refractory DLBCL
Mar 2021 - Mar 2021: Regulatory approval in Japan in combination with bendamustine and rituximab for relapsed/refractory DLBCL
Checkmark Data from trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for r/r DLBCL at ASH 2020
Checkmark Subgroup analysis data from trial for r/r DLBCL at ASH 2020
More
Completed
1/2
331
Europe, Canada, US, RoW
Bendamustine, Treanda; Ribomustin; Levact, Obinutuzumab, GA101; Gazyva; Gazyvaro, Polatuzumab vedotin (Liquid), DCDS4501A, Rituximab, Rituxan; MabThera, Polatuzumab vedotin (Lyophilized), DCDS4501S
Hoffmann-La Roche
Lymphoma
10/21
10/21
GO29834, NCT02600897 / 2015-001999-22: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Data from trial in combination with mabThera/rituxan and lenalidomide for r/r DLBCL
Jun 2021 - Jun 2021: Data from trial in combination with mabThera/rituxan and lenalidomide for r/r DLBCL
Checkmark From P1/2 trial in combination with Gazvya and lenalidomide in follicular lymphoma at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From P1/2 trial in combination with Gazvya and lenalidomide in follicular lymphoma at ASCO 2019 [screenshot]
Completed
1/2
114
Europe, US
Lenalidomide, Obinutuzumab, Polatuzumab Vedotin, Rituximab
Hoffmann-La Roche
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
12/21
12/21
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
GO29833, NCT02611323 / 2015-001998-40: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
1/2
133
Europe, US, RoW
Obinutuzumab, Rituximab, Polatuzumab Vedotin, Venetoclax
Hoffmann-La Roche, Genentech Inc. c/o F. Hoffmann La Roche Ltd.
Non-Hodgkin's Lymphoma
08/22
08/22
NCT02529852: A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Completed
1/2
59
US
Lenalidomide, CC-5013, Revlimid, Obinutuzumab, GA101, Gazyva, Cyclophosphamide, Cytoxan, Neosar, Doxorubicin, Doxorubicin Hydrochloride, Adriamycin PFS, Adriamycin RDF, Adriamycin, Rubex, Vincristine, Prednisone
M.D. Anderson Cancer Center, Celgene, Genentech, Inc.
Lymphoma
10/22
10/22
NCT04464798: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Active, not recruiting
1/2
62
Europe, US, RoW
CC-220, Iberdomide, Rituximab, Obinutuzumab
Celgene
Lymphoma
03/23
01/25
NCT02315768: Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Active, not recruiting
1/2
32
US
GA101, Obinutuzumab, ibrutinib
University of California, San Diego, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
11/23
11/23
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
NCT06357676: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Not yet recruiting
1/2
27
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
OHSU Knight Cancer Institute, Oregon Health and Science University, Genentech, Inc.
Mantle Cell Lymphoma
05/27
05/29
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
280
Europe, US, RoW
Glofitamab, RO7082859, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26
NCT04855695: Avo In R/R And Previously Untreated MCL

Recruiting
1/2
53
US
Acalabrutinib, Calquence, Acalabrutinib maleate, Venetoclax, Venclexta, Obinutuzumab, Gazyva
Austin I Kim, AstraZeneca, Genentech, Inc.
Mantle Cell Lymphoma, Refractory Lymphoma
12/24
06/26
NP30179, NCT03075696: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Checkmark Data from P2 portion of P1/2 trial for DLBCL
Dec 2022 - Dec 2022: Data from P2 portion of P1/2 trial for DLBCL
Checkmark Data from trial for 3L+ LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from trial for 3L+ LBCL at ASH 2022
Checkmark Safety and efficacy of phase 1/2 study for mantle cell lymphoma at ASH 2022
More
Recruiting
1/2
860
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, Gazyva®, Gazyvaro™, Tocilizumab, Actemra®, Roactemra®
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
08/25
08/25
NCT02229422: A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)

Active, not recruiting
1/2
40
US
GA101/HDMP
University of California, San Diego, Genentech, Inc.
CLL
10/25
12/25
CC-99282-NHL-001, NCT03930953: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting
1/2
438
Europe, Canada, US, RoW
CC-99282, BMS-986369, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Celgene
Lymphoma, Non-Hodgkin
04/26
04/27
C4971006, NCT05896163: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Recruiting
1/2
70
Japan, US, RoW
maplirpacept (PF-07901801), Glofitamab, Obinutuzumab
Pfizer, Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
06/26
06/28
iMATRIX GLO, NCT05533775 / 2021-006326-48: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
65
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
10/27
10/27

Download Options